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ABSTRACT
GBM (glioblastoma multiforme) is the most aggressive and
invasive form of primary human brain cancer. We recently
developedanovelbraincancer modelintheinbredVM mouse
strain that shares several characteristics with human GBM.
Using bioluminescence imaging, we tested the efficacy of CR
(calorie restriction) for its ability to reduce tumour size and
invasion. CRtargetsglycolysis and rapid tumour cellgrowth in
part by lowering circulating glucose levels. The VM-M3
tumour cells were implanted intracerebrally in the syngeneic
VMmouse host.Approx. 12–15 days post-implantation, brains
were removed and both ipsilateral and contralateral hemi-
spheres were imaged to measure bioluminescence of invading
tumour cells. CR significantly reduced the invasion of tumour
cells from the implanted ipsilateral hemisphere into the
contralateral hemisphere. The total percentage of Ki-67-
stained cells within the primary tumour and the total number
of blood vessels was also significantly lower in the CR-treated
mice than in the mice fed ad libitum, suggesting that CR is
anti-proliferative and anti-angiogenic. Our findings indicate
that the VM-M3 GBM model is a valuable tool for studying
brain tumour cell invasion and for evaluating potential
therapeuticapproachesformanaginginvasivebraincancer.In
addition, we show that CR can be effective in reducing
malignant brain tumour growth and invasion.
Key words: calorie restriction, glioblastoma multiforme, Ki-
67, VM mouse.
INTRODUCTION
Otto Warburg originally proposed that many cancers were
heavily dependent on glycolysis, even in the presence of
oxygen, suggesting an impairment in mitochondrial respira-
tion (Warburg, 1956). This aerobic glycolysis resulted in the
dependence of tumour cells on glucose for energy and
survival. Therefore exploiting abnormal brain tumour meta-
bolism has become an attractive approach for cancer manage-
ment in both human patients and in animal models (Seyfried
etal.,2003; SeyfriedandMukherjee,2005;Zuccolietal.,2010).
We previously showed that restricted caloric intake signifi-
cantly reduces the size and angiogenesis of mostly non-
invasive experimental mouse and human brain tumours
(Mukherjee et al., 2002, 2004; Zhou et al., 2007). CR (calorie
restriction) lowers circulating blood glucose levels, thereby
reducing carbohydrate energy for the tumour cells (Seyfried
et al., 2003; Seyfried and Mukherjee, 2005). In addition, CR
reduces free radical production and thus inflammation
(Veech, 2004; Seyfried and Mukherjee, 2005; Longo and
Fontana, 2010). Normal brain cells transition to ketone
bodies for energy, which become elevated under CR (Seyfried
and Mukherjee, 2005). Evidence in humans has confirmed
previous studies in mice that high blood glucose levels
predict poor prognosis for GBM (glioblastoma multiforme),
the most malignant and invasive form of adult primary brain
cancer (Seyfried et al., 2003; McGirt et al., 2008; Derr et al.,
2009). Although therapeutic fasting and a restricted
ketogenic diet was effective in managing GBM in an older
patient (Zuccoli et al., 2010), no prior studies have evaluated
the therapeutic effect of CR on invasive brain cancer in
mice.
We recently described the VM-M3 murine brain tumour
cell line, which is highly invasive when implanted ortho-
topically in the brain (Huysentruyt et al., 2008; Shelton et al.,
2010). The VM-M3 GBM model is the only known mouse
brain tumour expressing the ‘secondary structures of Scherer’
including diffuse parenchymal invasion, perivascular growth,
subpial surface growth and growth along white matter tracts
(Shelton et al., 2010). In the present study, we evaluated the
effect of CR on the proliferation and invasion of the VM-M3
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asnneuro.org / Volume 2 (3) / art:e00038 171tumour when grown orthotopically in its immunocompetent
syngeneic host. We found that CR significantly inhibited VM-
M3 growth and distal brain invasion.
MATERIALS AND METHODS
Mice
Mice of the VM/Dk (VM) strain were obtained as a gift from
Dr H. Fraser (University of Edinburgh, Edinburgh, Scotland,
U.K.). All mice used in the present study were housed and
bred in the Boston College Animal Care Facility using
husbandry conditions as described previously (Ranes et al.,
2001). All mice received Prolab RMH 3000 chow (LabDiet).
The diet contains a balance of mouse nutritional ingredients
and delivers 4.4 kcal/g gross energy, where fat, carbohydrate,
protein and fibre comprised 55, 520, 225 and 45 g/kg of the
diet respectively. All animal procedures were in strict
accordance with the NIH (National Institutes of Health)
Guide for the Care and Use of Laboratory Animals and were
approved by the Institutional Animal Care Committee.
Tumour formation
The VM-M3 tumour arose spontaneously in the cerebrum of
an adult male VM mouse as described previously (Huysentruyt
et al., 2008). The tumours were grossly identified in the
cerebrum similar to those described previously for other
spontaneous tumours in the VM mouse brain (Fraser, 1986;
El-Abbadi et al., 2001). In order to preserve in vivo viability,
the tumour was immediately resected and implanted i.c.
(intracerebrally) into host VM mice as described below. As
soon as cranial domes appeared, the tumours were passaged
again into several host VM mice. After a total of three i.c.
passages, the tumours were grown s.c. (subcutaneously) and
cell lines were prepared from the tumour as described
previously (Huysentruyt et al., 2008).
Transduction of cell lines
The VM-M3 cell line was transduced with a lentivirus vector
containing the firefly luciferase gene under control of the
cytomegalovirus promoter (VM-M3/Fluc) described previously
(a gift from Dr Miguel Sena-Esteves, Neuroscience Center at
Massachusetts General Hospital, Charleston, MA, U.S.A.)
(Huysentruyt et al., 2008).
Tumour implantation
Tumour implantation was performed as described previously
(Ranes et al., 2001). Briefly mice were anaesthetized with
Avertin (0.1ml/10 g of body weight). The tops of the heads
were disinfected with ethanol and a small incision was made
in the scalp of the mouse over the midline. A 3 mm
3 burr hole
was made in the skull over the right cerebral hemisphere.
Using a trocar, a small tumour fragment (1 mm
3) was
implanted into the hole made in the skull. The flaps of skin
were then immediately closed with collodion adhesive. The
mice were placed in a warm room (37˚C) until they fully
recovered.
Imaging
The Xenogen IVIS system was used to record the biolumin-
escent signal from the labelled tumours as we described
recently (Huysentruyt, et al. 2008; Shelton et al., 2010).
Briefly, mice received an intraperitoneal injection of D-
luciferin (50 mg/kg of body weight; Promega) in PBS and
Avertin (0.1 ml/10 g of body weight) prior to imaging.
Imaging times ranged from 3 to 10 min, depending on the
time point. Longer imaging times were used initially to assess
tumour ‘take’, i.e. that tumours were actually growing in the
mice. For ex vivo imaging, brains were removed and sectioned
through the midline. Individual hemispheres were imaged
separately in 300 mg/ml D-luciferin in PBS, and imaged from 3
to 10 min. Identical imaging times were used for both AL (ad
libitum) and CR groups for each hemisphere. However, the
contralateral hemisphere was imaged for a longer period than
the ipsilateral hemisphere to ensure detection of the invasive
tumour cells. The IVIS Lumina cooled CCD (charge-coupled-
device) camera system was used for light acquisition. Data
acquisition and analysis was performed with Living ImageH
software (Caliper LS).
Dietary regimens, body weight and food intake
measurements
Adult male and female VM mice (approx. 60–90 days old)
were individually housed 1–2 days prior to tumour cell
implantation. Mice were kept in filter-topped plastic cages
containing Sani-Chip bedding (P.J. Murphy Forest Products
Corporation). Body weight and food intake was recorded daily
and standard chow was provided AL. Tumour fragments were
implanted on day zero (Figure 1A). The mice were then
matchedfor body weight andseparated into twogroups (AL and
CR) 4–6 days post-implantation. Imaging confirmed the
presence of a growing tumour in each implanted mouse. Mice
were administered the standard chow diet either AL
or restricted to 40% of their normal food intake (60%
restriction) at approx. the same time (10:00 hours) each
day. All mice were weighed daily prior to food administra-
tion. Mice were sacrificed at the time of morbidity, which
was approx. 12–15 day post-implantation for the control AL
mice (Figure 1A).
Plasma glucose measurements
Mice were anaesthetized with isoflurane (Halocarbon Labo-
ratories) and euthanized by exsanguination, involving
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(Marsh et al., 2008b). Both the AL and the CR groups were
fasted 3–4 h before being sacrificed. The blood plasma was
collected and centrifuged at 4000 g for 20 min and was
stored at 280˚C until analysis. Plasma glucose concentration
was measured in a spectrophotometer using the Stanbio
Enzymatic Glucose Procedure.
Ketone determination
The ketone body b-OHB (b-hydroxybutyrate) was measured
enzymatically in plasma or serum with a modification of the
procedure described by Williamson et al. (1962).
Histology
Brain tumour samples were fixed in 10% neutral-buffered
formalin (Sigma) and embedded in paraffin. The brain
tumour samples were sectioned at 5 mm, were stained with H
& E (haematoxylin and eosin) at the Harvard University
Rodent Histopathology Core Facility (Boston, MA, U.S.A.) and
were examined by light microscopy using either a Zeiss
Axioplan 2 or Nikon SMZ1500 light microscope as we
described previously (Mukherjee et al., 2002). Images were
acquired using SPOT Imaging Solutions (Diagnostic
Instruments) cameras and software. All histological sections
were evaluated by a veterinary neuropathologist (Roderick
Bronson) at the Harvard University Rodent Histopathology
Core Facility.
Immunohistochemical staining
The brain tissue sections were deparaffinized, rehydrated and
washed as described previously (Mukherjee et al., 2004).
Sections that were stained with Factor VIII were incubated
with trypsin at 37˚C for 30 min following deparaffinization
and rehydration. The tissue sections were then heat-treated
(95˚C) in antigen unmasking solution (Vector Laboratories)
for 30 min. Tissue sections were blocked in goat serum (1:10
in PBS) for 1 h at room temperature (22–25˚C) and treated
with either Ki-67 primary antibody (rat monoclonal used at
1:100; Dako), or Factor VIII primary antibody (rabbit
polycolonal used at 1:100; Dako), overnight at 4˚C, followed
by a biotinylated anti-rat or anti-rabbit secondary antibody
at a 1:100 dilution (Vector Laboratories). The sections were
then treated with avidin–biotin complex followed by 3,39-
diaminobenzidine as the substrate for staining according to
the manufacturer’s protocol (Vectastain Elite ABC kit; Vector
Laboratories). The sections were counterstained with haem-
atoxylin (Ki-67) or Methyl Green (Factor VIII) and mounted.
Corresponding tissue sections without primary antibody
served as negative controls. A Zeiss Axioplan 2 light
microscope was used to capture bright-field images as
described above. The percentage of Ki-67-positive cells were
determined using a Photoshop-based image analysis as
described previously (Lehr et al., 1999). MVD (microvessel
density) was quantified by examining areas of vascular hot
spots as described previously by Weidner et al. (1991), with
some modifications (Mukherjee et al., 2004). Sections were
scanned at low magnification (640 and 6100) for the
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Figure 1 Study design and influence of CR on body weights and plasma glucose levels
(A) VM mice were implanted with VM-M3/Fluc tumour fragments as described in the Material and methods section and were given a
60% CR starting on days 4–6. Brains were removed 12–15 days post-implantation and imaged ex vivo.( B) The body weights of the
VM mice were monitored daily. Values represent the means¡S.E.M. for 9–10 mice per group. VM mice were sacrificed and plasma
was collected for the analysis of glucose (C) and ketones (D) as described in the Materials and methods section. Values represent the
means¡S.E.M. The * indicates that the CR values differ significantly from those of the AL control group at P,0.05 using the two-
tailed Student’s t test.
CR inhibits tumour invasion
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173localization of vascular hot spots. The three most vascular
areas of the tumour not containing necrosis were determined
and then counted at higher magnification (6200). The values
of the three sections were averaged for all tumours.
RESULTS
No prior studies have evaluated the influence of CR against
invasive brain cancer in mice. The objective of the present
study was to determine whether CR could be effective for
managing contralateral hemispheric invasion of VM-M3
tumour cells.
Effect of calorie restriction on body weights, and
plasma glucose and ketones
We first evaluated the effect of a 60% dietary restriction on
body weights and plasma glucose (Figure 1). CR significantly
reduced the body weights of the mice by the end of the study
(Figure 1B). In addition, circulating glucose levels were
significantly lower in the CR group than in the control AL
fed group (Figure 1C). Circulating ketone levels were
significantly higher in the CR group than in the AL group
(Figure 1D).
Effect of calorie restriction on tumour growth
and invasion
As seen in Figure 2, CR reduced the growth and invasion of
the VM-M3 primary tumour. Compared with the diffuse, ill-
defined border of the VM-M3 tumour observed in the AL-fed
control mice, the tumour grown in the CR mice appeared
denser with a more defined border. We evaluated the level of
invasion into the contralateral hemisphere using biolumin-
escent imaging as described in the Materials and methods
section. The total amount of bioluminescence in the
contralateral hemisphere was significantly less in the CR-
fed mice than in the AL-fed mice (Figure 3). Histology was
used to confirm the extent of tumour-cell invasion into the
contralateral hemisphere between the AL and CR groups. As
shown in Figure 4, invading tumour cells were identified in all
regions of the contralateral hemisphere of the AL-fed mice
(arrows). In contrast, we identified sub-pial spread only to the
cortex in the contralateral hemisphere of the CR group. The
number of migrating cells was also noticeably less in the CR-
fed mice than in the AL-fed mice (Figure 4). In addition, the
percentage of Ki-67-positive tumour cells was significantly
lower in the CR mice than in the AL mice (Figure 5). Factor
VIII staining was used to measure blood vessel density in the
tumours (Figure 6). Blood vessel density was significantly
lower in the primary tumours of CR mice than in the AL mice.
Blood vessel size was also smaller in the tumours of the CR
mice than the AL mice (Figure 6).
DISCUSSION
We found that CR, which significantly reduces tumour
growth and angiogenesis in the non-invasive murine and
human experimental models (Mukherjee et al., 2002, 2004;
Zhou et al., 2007), also reduced tumour growth and invasion
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Figure 2 Influence of CR on VM-M3/Fluc tumour growth
VM-M3/Fluc tumour fragments were implanted as described in Figure 1. Post-imaging, brains were fixed and stained with H & Ea s
described in the Materials and methods section. Images are shown at 506 (T, tumour; H, hippocampus). At least three samples were
examined per group.
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(Shelton et al., 2010). Previous studies in mice showed that
high blood glucose levels were predictive of rapid glioma
growth and angiogenesis (Mukherjee et al., 2002; Seyfried et
al., 2003; Marsh et al., 2008a). Recent studies in humans have
also linked high circulating glucose levels with poor prognosis
in patients with GBM (McGirt et al., 2008; Derr et al., 2009).
Additionally, a restricted ketogenic diet has been introduced
into the clinical setting with positive results in both children
and in an older adult (Nebeling et al., 1995; Zuccoli et al.,
2010). Because most brain tumours are highly glycolytic, they
rely heavily on glucose as a major energy source (Warburg,
1956; Seyfried and Mukherjee, 2005). CR lowers circulating
glucose and targets those pathways associated with tumour
glycolysis (Seyfried et al., 2003; Seyfried and Mukherjee,
2005; Marsh et al., 2008; Seyfried and Shelton, 2010). In
addition to reducing glucose, CR also elevates circulating
ketone bodies that are metabolized for energy by normal
brain cells when glucose levels are reduced (Seyfried and
Mukherjee, 2005; Zhou et al., 2007). Ketone body metabolism
takes place in the mitochondria and provides non-glucose-
derived reducing equivalents for oxidative phosphorylation.
The VM-M3 cell line, however, has alterations in both
mitochondrial lipid composition and electron transport chain
enzyme activities, which would compromise normal mito-
chondrial function (Kiebish et al., 2008). In addition, the VM-
M3 cell line was unable to transition to ketones under
low-glucose conditions in vitro, whereas normal astrocytes
successfully grew under low-glucose, high-ketone conditions
(L.M. Shelton and T.N. Seyfried, unpublished data). These
findings indicate that brain tumour cells are more sensitive to
energy stress than normal brain cells and can be targeted
through principles of metabolic control theory (Seyfried and
Mukherjee, 2005; Seyfried et al., 2008).
We and others previously showed that dietary energy
restriction could reduce IGF-1 (insulin-like growth factor 1)/
PI3K (phosphoinositide 3-kinase)/Akt/HIF-1a (hypoxia-indu-
cible factor 1a) signalling, which drives tumour cell growth
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Figure 3 Influence of CR on bioluminescence in the contralateral
hemisphere
VM-M3/Fluc tumour fragments were implanted as described in Figure 1. Each
hemisphere was imaged for bioluminescence ex vivo as described in the
Materials and methods section. The bioluminescence from each hemisphere
was added together to obtain a total bioluminescence value (photons/s) for
each brain. Data for the contralateral hemisphere was then expressed as the
percentage of the total brain photons/s. Values represent the means¡S.E.M.
for 9–10 mice per group. Representative bioluminescence images are shown.
The * indicates that the CR values differ significantly from the AL control
group at P,0.05 using the two-tailed Student’s t test.
Figure 4 Influence of CR on VM-M3/Fluc tumour cell invasion to the contralateral hemisphere
VM-M3/Fluc tumour fragments were implanted as described in Figure 1. Histological analysis (H&E) was used to validate the
presence of tumour cells under AL (top panels) and CR (bottom panels) in cerebral cortex (2006), hippocampus (1006), cerebellum
(1006) and brain stem (2006). Arrows indicate the presence of tumour cells. At least three samples were examined per group.
CR inhibits tumour invasion
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175and metabolism (Marsh et al., 2008; Moore et al., 2008).
Previous studies also showed that CR lowers circulating levels
of IGF-1 and VEGF (vascular endothelial growth factor),
which stimulate angiogenesis (Kari et al., 1999; Seyfried et al.,
2003; Zhu et al., 2003; Mukherjee et al., 2004). In the present
study we showed that CR also significantly reduced the
percentage of Ki-67-positive tumour cells, an indicator of cell
proliferation (Li et al., 2009). High Ki-67 expression is a
negative prognostic factor for patients with GBM (Persson
and Englund, 2008; Li et al., 2009). We also found that VM-
M3 blood vessel density and size was significantly lower in
CR-treated mice than in mice fed AL. Viewed collectively,
these findings indicate that the anti-invasive properties of CR
can be due, in part, to a reduction of proliferative, glycolytic
and angiogenic factors.
CR significantly reduced tumour invasion into the
contralateral hemisphere, but did not completely inhibit all
invasion. We previously showed that a restricted ketogenic
diet used in combination with 2DG (2-deoxy-D-glucose), a
potent glycolysis inhibitor, achieved synergy with regard
to reductions in tumour size (Marsh et al., 2008). The
mechanisms by which CR reduces VM-M3 cell invasion is not
yet clear, but could involve a reduction in angiogenesis,
which correlates with invasion and is significantly reduced
under CR as we previously showed (Mukherjee et al., 2002,
2004; Lakka and Rao, 2008). The anti-inflammatory properties
of ketone body metabolism might also, in part, reduce
tumour cell invasion. We suggest that CR or restricted
ketogenic diets can be used in conjunction with low-dose
chemotherapeutic agents to enhance efficacy while reducing
drug toxicity. Recent studies in humans also showed that
fasting could enhance the therapeutic efficacy of chemo-
therapy (Safdie et al., 2009). In conclusion, in the present
study we found that CR significantly reduced invasion and
proliferation of the VM-M3 model of invasive brain cancer,
suggesting that diets which lower glucose and elevate ketone
levels can be therapeutic for invasive brain tumours.
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